3clinical efficacy and safety of bisphosphonates

... characteristics of the eligible clinical trials Table displayed Fig Flow chart of the selection process Page of 13 the details of therapeutic regimens and rates of OS, FFS, objective response, and grade ... because of the absence of complete efficacy and safety data, conference abstracts were excluded, (8) studies were published in English Any disagreements were resolved by discussion Data extraction and ... throughout the course of treatment, and higher relative risks of grade or more thrombocytopenia and vomiting during CCRT Background Nasopharyngeal carcinoma (NPC) is one of head and neck tumors with

Ngày tải lên: 30/05/2020, 21:36

... translation of therapeutic potential of mycophenolate mofetil emerging from in vitro and animal studies into the clinical domain It is designed to assess the efficacy and safety of mycophenolate mofetil ... clinical trial evaluating the efficacy and safety of Mycophenolate Mofetil in patients with high-grade locally advanced or metastatic osteosarcoma (ESMMO): rationale and design of the ESMMO trial Nut ... objective is to assess the safety and tolerability of the drug The present study also aims to explore the pharmacokinetics of mycophenolate mofetil, biomarkers, and the quality of life in patients with

Ngày tải lên: 17/06/2020, 11:32

... the efficacy and safety of concurrent EP versus PC chemotherapy with radiotherapy for LA-NSCLC Patients were stratified by institution and stage before randomization The Ethics Committee of the ... patients capable of all self-care with bed rest for less than 50% of daytime as ECOG subgroup The aims of the present subgroup analyses were (1) explore the efficacy and safety of concurrent chemoradiotherapy ... RESEARCH ARTICLE Open Access Efficacy and safety of concurrent chemoradiotherapy in ECOG patients with locally advanced non-small-cell lung cancer: a subgroup analysis of a randomized phase III trial

Ngày tải lên: 17/06/2020, 11:38

... based on the descriptive objectives of the study Thus, for estimating a characteristic with a relative frequency of 10% and a precision of ±4%, and assuming that 5% of patients will be excluded from ... Ipsen, Novartis, Eusa Pharma, Eisai and Sanofi; and as speaker from Kyowa, PierreFabre, Celgene, Lilly and Merck; and has received travel grants from Pfizer, Roche and BMS AGA has received honoraria ... Pharma, Eisa and Sanofi, and as speaker from Lilly, Astellas, Bayer, Roche, Boehringer, Ipsen, Novartis, astra Zeneca and Sanofi; he has received travel grants from Pfizer, Roche and Astra Zeneca

Ngày tải lên: 17/06/2020, 17:10

... dose, efficacy and safety of this treatment differs from those of other pertuzumab-based dual anti-HER2 therapies remain controversial This systematic review evaluates the efficacy and safety of ... ratios (HRs) and 95% confidence intervals (CIs) were pooled for PFS and OS, and the number of events extracted directly from clinical trials was used to calculate the OR and 95% CI of pCR and adverse ... all-grade AEs (rash, diarrhea, and mucosal inflammation) or AEs of grade ≥ (diarrhea), the risk of H + P group was higher than that of H group and P group, and the risk of P group was the lowest among

Ngày tải lên: 17/06/2020, 18:10

... based on randomized controlled trials, the safety and efficacy of 25 and 20 mg/m2 in real-world settings are not well established Therefore, we investigated the safety and efficacy of cabazitaxel ... safety and efficacy of cabazitaxel between patients who received cabazitaxel at starting doses of 25 and 20 mg/m2 (C25 and C20, respectively) in a Japanese post-marketing surveillance study of ... Janssen, AstraZeneca, Sanofi, Taiho, Novartis, Bayer, and Chugai, and research grants from Janssen, Sanofi, Bayer, Shionogi, Chugai, and MSD HK, TS, and ST are employees of Sanofi KS has received

Ngày tải lên: 06/08/2020, 05:35

... meta-analyses published between 2009 and 2012 compiled the results of randomized trials on standard chemotherapy with bevacizumab in the therapy of mCRC [16–19] Results of these metaanalyses evidenced ... the role of Page of 19 bevacizumab as a component of first-line therapy in patients with advanced colorectal cancer This systematic review aims to evaluate the effectiveness and safety of bevacizumab ... validity of each selected trial assessed by two reviewers (T.E.A.B and O.C) Particular attention was given to some items such as: the generation and concealment of the sequence of randomization,

Ngày tải lên: 20/09/2020, 17:53

... first generation EGFR-TKI and chemotherapy We prospectively evaluated the efficacy and safety of afatinib in Chinese patients who previously failed first-generation TKI and chemotherapy under a ... analysis, we prospectively evaluated the efficacy and safety profiles of afatinib as 3rd or 4th line treatment after prior failure to systemic chemotherapy and first-generation EGFR-TKI under a ... permanently if they developed grade ≥3 events Assessment of efficacy and safety profiles All treatment-related toxicities were collected and graded according to Common Terminology Criteria for

Ngày tải lên: 21/09/2020, 02:04

... Overall, the safety and efficacy profiles of nab-paclitaxel in this setting of US women with MBC were consistent with clinical trial experience (Table 1) [10–19] Our analysis showed a median OS of 17.4 ... agents for the treatment of MBC (Table 1) [14–19] Results of phase two trials of nab-paclitaxel in combination with gemcitabine and oral capecitabine have demonstrated efficacy and favorable tolerability ... (defined as 30 days) of treatment prior to being defined as switching to a greater line of therapy Any switching or addition of agents within 30 days of the start of each line of therapy was considered

Ngày tải lên: 21/09/2020, 10:20

... 2–3% of the infant population and a large proportion of neonatal admissions This population of preterm infants often requires transient respiratory support, are at risk of hypoglycemia and feed ... were ineligible Infants were required to be enrolled and randomised before 24 h of age Randomisation and blinding Infants were randomised to one of two groups: the peripheral parenteral nutrition ... intravenous site at g/kg/d and was included in the total amount of intravenous daily fluids For the period prior to randomisation and commencement of the intervention Page of 10 solutions, infants

Ngày tải lên: 21/09/2020, 13:48

... group and 89.3 % in the sunitinib and Page of 11 lanreotide group and at 12 months it was 68.6 and 73.0 %, in the everolimus and sunitinib patient groups, respectively At 18 months, 57.0 % of patients ... (2015) 15:495 Page of 11 Table Number of adverse events (AEs) and Grade or AEs reported during the study and assignment of causality to the treatment received The number of Grade and AEs is shown ... combination of lanreotide and targeted therapies, mainly everolimus and sunitinib, is widely used in clinical practice without unexpected toxicities and suggests efficacy that should be explored in randomized

Ngày tải lên: 28/09/2020, 09:59

... (RECIST) version 1.0 [33] Page of 10 Tumour evaluations were undertaken at baseline and at the end of each treatment cycle Safety and tolerability The safety and tolerability of nintedanib were assessed ... two-part phase II study of cediranib in patients with advanced solid tumours: the effect of food on singledose pharmacokinetics and an evaluation of safety, efficacy and imaging pharmacodynamics ... double-blind study to investigate efficacy and Mross et al BMC Cancer 2014, 14:510 http://www.biomedcentral.com/1471-2407/14/510 51 52 53 54 55 56 Page 10 of 10 safety of two doses of the triple angiokinase

Ngày tải lên: 14/10/2020, 13:28

... identification of only a small number of RCTs and the lack of comparability in terms of sample size, study design, and patient populations across both the RCTs and non-randomised studies The patient ... variability was often observed in the efficacy and safety results, primarily attributed to differences in patient characteristics and assessment criteria used to evaluate efficacy measures Page 17 of 21 ... Central Register of Controlled Trials, and Cochrane Database of Systematic Reviews) were searched from 1980 to 01 March 2012 to identify randomised controlled trials (RCTs) and non-randomised studies

Ngày tải lên: 05/11/2020, 05:59

... amendments (Nos and 2), informed consent documents, and other appropriate study-related documents were reviewed and approved by the Ministry of Health of Ukraine Central Ethics Committee and local ... receiving chemotherapy This phase III, double-blind, randomized, active-controlled, noninferiority trial compared the efficacy and safety of lipegfilgrastim versus pegfilgrastim in chemotherapy-naïve ... primary efficacy endpoint was the duration of severe neutropenia during cycle Results: Cycle 1: The mean duration of severe neutropenia for the lipegfilgrastim and pegfilgrastim groups was 0.7 and

Ngày tải lên: 05/11/2020, 05:59

... https://doi.org/10.1186/s12871-019-0910-8 RESEARCH ARTICLE Open Access Efficacy and safety of prophylactic use of ketamine for prevention of postanesthetic shivering: a systematic review and meta analysis Yang Zhou1†, Abdul Mannan1†, ... lack of high-quality evidence, it is difficult to draw a conclusion about optimal anti-shivering medication The main purpose of this meta-analysis was to analyze and evaluate the efficacy and safety ... and safety of prophylactic use of ketamine for preventing postanesthetic shivering Methods: We searched the following databases: Medline, Embase, and the Cochrane Central Register of Controlled

Ngày tải lên: 13/01/2022, 01:17

... and Risk of Bias In Non-randomized Studies of Interventions (ROBINS-I) We conducted narrative evidence synthesis and assessed the conclusiveness of included studies regarding efficacy and safety ... comparator, inclusion and exclusion criteria, number of participants, baseline characteristics of participants, followup period, DRG level treated and outcomes about efficacy and safety Risk of bias assessment ... we conducted a narrative and tabular synthesis of results We also conducted an analysis of conclusiveness about efficacy and safety of the treatment in the abstracts of included studies We divided

Ngày tải lên: 13/01/2022, 01:38

... Hypnotics and sedatives were used by 25% of aripiprazole patients and 21% of placebo patients At least adverse event was reported by 142 (76%) of the 186 patients in the placebo group and 154 (87%) of ... validity of psychiatric diagnosis perplexes the problem and makes the gathering of scientific data difficult, because the diagnosis of BD in particular is often made retrospectively and carries ... the role of the 5-HT-mediated systems in the mechanism of action of aripiprazole [33] Aripiprazole reaches peak concentration (Cmax) to h after ingestion, and has a bioavailability of 87% and half...

Ngày tải lên: 08/08/2014, 23:21

... double-blind and placebo-controlled clinical study, we sought to evaluate the efficacy and safety of 5-Loxin® in treatment of OA of the knee We assessed the effectiveness of 100 mg/day and 250 mg/ ... Haematological and biochemical evaluations For assessment of safety of 5-Loxin®, several parameters were evaluated in serum, urine and whole blood of all patients at each visit of the study duration ... analyses using SAS software to evaluate the efficacy of two doses of 5-Loxin® in comparison with the placebo group in terms of improvement in pain and physical ability scores, and to assess biomolecular...

Ngày tải lên: 09/08/2014, 10:23

... Analysis of days of onset of common cold symptoms Shown are the numbers of patients for verum, placebo and total divided into groups with days of onset of common cold symptoms at the point of inclusion ... clear, colourless, odourless and free of particles Verum and placebo nasal sprays were identical in shape, size and colour to allow a double-blind design, and were randomized at the CRO Before ... patient 23 reported migraine and puffy eye lids, used ibuprofen and anti-histamine as concomitant medication and was therefore excluded from the efficacy analysis of symptoms One Iota-Carrageenan...

Ngày tải lên: 12/08/2014, 11:22

... (breathlessness on a scale of to 4; cough, sputum production and wheezing on a scale of to 3), use of daily rescue medication and concomitant medication were recorded in the patient’s diary and reviewed by ... in favour of aclidinium for cough and sputum production (Week 1), breathlessness (Week 12), wheezing (Week 28) and use of daily rescue medication (Weeks 12 and 28) (p < 0.05 for all) Safety The ... Pneumology and Thoracic Surgery, Grosshansdorf, Germany 6Department of Oncology, Haematology and Respiratory Diseases, University of Modena and Reggio Emilia, Modena, Italy 7Division of Pulmonary...

Ngày tải lên: 12/08/2014, 13:22